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Factors associated with sexual dysfunction
in Taiwanese females with rheumatoid
arthritis
Miao-Chiu Lin1†, Ming-Chi Lu2,3†, Hanoch Livneh4†, Ning-Sheng Lai2,3, How-Ran Guo5,6,7* and Tzung-Yi Tsai7,8,9*

Abstract
Background: Patients with rheumatoid arthritis (RA) may experience sexual dysfunction because of symptoms or
adverse effects from treatments. Data on female sexual dysfunction (FSD) in Asian females with RA issue are limited.
This study investigated the prevalence and factors associated with FSD in Taiwanese patients with RA.
Methods: This cross-sectional study used a purposive sampling method to recruit 195 females with RA from a single
hospital in southern Taiwan. Demographic and clinical characteristics were obtained by review of medical records and
a structured questionnaire. The Chinese version of the Female Sexual Function Index and the Taiwanese Depression
Questionnaire were also administered. Multiple logistic regression analysis was used to identify factors
associated with FSD.
Results: The crude and age-standardized prevalence of FSD were 66.8% and 48.2%, respectively. Patients who were
older, with a comorbid condition, with more depressive symptoms, and with greater disease activity had a significantly
higher risk of FSD.
Conclusion: Our findings indicate that FSD is more common in Taiwanese individuals with RA who have certain specific
demographic and clinical characteristics. These findings may help to identify and facilitate the provision of appropriate
interventions to ensure better sexual health in female patients with RA.
Keywords: Sexual dysfunction, Female, Rheumatoid arthritis, Taiwan

Background
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by inflammation and progressive
damage of the joints that affects 0.5–1.0% of the population
worldwide [1]. RA onset usually occurs in individuals who
are 30 to 50 years old, and about 20–30% of affected individuals report some arthritis-attributable work limitations,
with major burdens to patients, families, and social care
systems [2]. Gabriel and colleagues [3] estimated the direct
annual costs for care of an RA patient was US$3802 in
1987 (corresponding to US$5763 in 2000), approximately
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six-times higher than for an individual without RA.
Additionally, the annual total societal costs (sum of direct,
indirect, and intangible costs) was estimated to exceed
US$39 billion [4].
There have been massive increases in specialized diagnostic and therapeutic methods, and this has improved
the survival of RA patients in recent decades. However,
some treatments may lead to the onset of negative
sequelae, such as fatigue, sadness, and physical changes,
and these may influence a patient’s sexual function and
desire for sexual intercourse. Previous research estimated that about 46% to 75% of females with RA had
female sexual dysfunction (FSD) [5–9], which was
approximately twice as high as for the healthy women
[10]. Notably, most women develop RA between the
ages of 30 and 50 years, which is within the age range
for pregnancy. Accordingly, the reduced sexuality that
accompanies RA leads to deterioration in quality of life
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(QOL) and family function, and may also result in divorce [5]. In view of this, eliminating FSD in RA patients has become a primary priority in healthcare
practice [11, 12].
Most studies of FSD in individuals with RA have been
conducted in Western countries [5, 8, 9, 13, 14]. Due to
the more conservative Asian culture, Chinese people
often regard sex as a taboo subject and are more reluctant to openly talk about their sex lives [15]. Thus, a review of the literature indicated that most studies of RA
in Taiwan have focused on the effects of medical therapy
[16], ambulatory care utilization [17], and disease epidemiology [18]. There is very little known about FSD in
Chinese individuals with RA. So this study aimed to
examine the prevalence and factors associated with FSD
in RA patients from Taiwan. The findings of this study
could serve as a reference for the recognition of FSD in
Chinese individuals with RA as well as may be useful for
implementation of interventions.

Methods
Study design and population

This is a cross-sectional study of female outpatients and
inpatients with RA who were recruited consecutively
from July 2014 to June 2015 at a single hospital in
southern Taiwan (Dalin Tzuchi Hospital, Chiayi,
Taiwan). The inclusion criteria were as follows: (i) aged
20 years or older; (ii) no cognitive impairments and with
the ability to express opinions in Mandarin or Taiwanese;
(iii) sexually active for at least 2 years before the diagnosis
of RA; and (iv) awareness of the diagnosis of RA and
agreement to participate in the survey. The sample size
needed for this study was determined as described by Cohen [19]. For an α of 0.05, power of 0.8, and effect size of
0.15, this analysis indicated the need for a sample size of
at least 150 patients.
Instruments

Three measures were used to survey the enrolled
patients: the Taiwanese Depression Questionnaire (TDQ),
the Female Sexual Functional Index (FSFI), and a questionnaire that requested information on demographic
variables and clinical characteristics.
To assess the presence of depressive symptoms, we administered the TDQ which was created by Lee et al. and
was developed specifically to meet the needs of the
Asian culture [20]. The test is comprised of 18 items,
each of which assesses symptoms during the past one
week, using a scale of 0 (absence of symptoms) to 3
(presence of symptoms almost every day). The total
score therefore ranges from 0 (no depression) to 54 (significant depression). Based on comparison with the
Structured Clinical Interview for DSM Disorders (SCID)
as the gold standard, the TDQ had good concurrent

Page 2 of 7

validity, and the area under the receiver operating characteristic (ROC) curve was 0.92. The TDQ performed
optimally using a cutoff value of 19 in detecting depressive symptoms in patients with chronic diseases or from
the general population [21, 22]. Assessment of test reliability indicated that the TDQ had good internal
consistency among different groups of subjects, and
Cronbach’s α ranged from 0.89 to 0.92 [21–23]. Cronbach’s α from the present data was 0.91.
The Female Sexual Function Index (FSFI), developed
by Rosen and colleagues [24], was used to measure FSD.
This 19-item questionnaire was developed as a brief,
multidimensional self-reporting instrument to assess the
key dimensions of sexual function over the previous four
weeks in six domains: desire, subjective arousal, lubrication, orgasm, satisfaction, and pain. The total score was
obtained by adding the six separate domain scores, and
ranged from 2.0 to 36.0. A lower score indicated more
severe FSD. Previous studies have evaluated the FSFI for
discriminant validity, divergent validity, concurrent
validity, and test-retest reliability [24–26]. In clinical
practice, an FSFI cut-off score of 26.55 has been widely
used to define FSD [15, 27]. This test was translated into
Chinese by Kuo et al., and Cronbach’s α was 0.81 to 0.92
for all domains in the Chinese version [28]. Cronbach’s α
from the present study yield a coefficient of 0.91.
We also used questionnaires that assessed demographic and clinical characteristics that were based on a
review of previous literature and clinical experience. The
demographic data included age, marital status, educational
level, job status, living status, religious beliefs, and
certain lifestyle factors such as smoking and exercise
habits. Those who answered “currently” or “yes/past”
to smoking were classified as smokers. Those who
exercised 3 or more days per week were classified as
having regular exercise habits. The clinical characteristics included the following: chronic disease (diabetes
mellitus, hypertension, heart disease, or stroke), body
mass index (BMI), Disease Activity Score in 28 Joints
(DAS28), serum C-reactive protein (CRP), duration of
RA, menopausal status (premenopause or postmenopause), depressive symptoms, self-reported pain based
on a visual analog scale (VAS), and use of biological
disease-modifying anti-rheumatic drugs (DMARDs),
such as Etanercept, Adalimumab, Infliximab, or Rituximab. For this last variable, participants were asked
whether they had ever used these biological DMARDs
for more than 3 months after RA onset. All clinical
characteristics were obtained by chart review.
Data collection

This study was approved by the Institutional Review
Board of Dalin Tzuchi Hospital. Before enrolling in the
study, all participants received detailed written and
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verbal information regarding the aims and protocol of
the study and signed an informed consent. The
researchers were available to answer any inquiries during
completion of the questionnaires. For illiterate patients,
the researchers read the questionnaires and recorded answers. All questionnaires were returned without any
identifying personal information and were only marked
with an encryption code to facilitate data analysis. The
encryption rules were available for the researchers only.
Statistical analysis

Descriptive and inferential statistical analyses were
conducted in accordance with the study aims and the
nature of variables. Descriptive statistics (mean and
standard deviation [SD]) were used to describe the
demographic and clinical characteristics. For inferential analysis, a t-test or chi-square test was used to
identify the relationships of demographic and clinical
characteristics with FSD (cut off score of 26.55). Variables significantly related to FSD in the univariate
analysis were entered into a multiple logistic regression to compute adjusted odds ratios (aORs) and 95%
confidence intervals (CIs). The α value was set at
0.05 for all statistical analyses.

Results
Demographic and clinical characteristics of participants

During the recruitment period, we approached 195
women with RA. Among them, 131 met the criteria for
FSD based on an FSFI score of 26.55 or less (crude
prevalence: 66.8%). After adjusting for age based on the
2000 World Standard Population [29], the agestandardized prevalence of FSD was 48.2%. Thus, about
half of the individuals with RA in this sample suffered
from FSD.
The mean age of participants was 53.76 years old
(±8.89), and most of them were married (92.9%), unemployed (55.1%), cohabitating (92.9%), and with a high
level of education (55.1%). In addition, most participants
had religious beliefs (85.2%), did not smoke (95.4%), engaged in regular exercise (67.9%), and were in menopausal status (63.8%). The mean duration of RA was
9.72 years (±6.02). Nearly 70% of the participants reported use of a biological DMARD, and 44.4% had a comorbid condition. The overall mean BMI, DAS28 score,
serum CRP level, pain score, and TDQ score were 24.00,
3.77, 0.94, 3.18, and 12.28, respectively (Table 1).
FSFI scores

The mean FSFI score was 11.87, with a SD of 7.05.
Of the six domains of this index, “satisfaction” was
found to reveal the highest standardized score, 54.19,
whereas “arousal ” showed the lowest standardized
score of 23.8 (Table 2).
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Table 1 Demographic and clinical characteristics of enrolled
Taiwanese females with RA (n = 196)
Variable

Mean ± SD

N (%)

Demographic characteristics
Educational level
High (≥9th grade)

108 (55.1)

Low (<9th grade)

88 (44.9)

Martial status
Married

182 (92.9)

Single

14 (7.1)

Working status
Employed

88 (44.9)

Unemployed

108 (55.1)

Living status
Living alone

14 (7.1)

Cohabitating

182 (92.9)

Religious beliefs
Yes

167 (85.2)

No

29 (14.8)

Cigarette smoking
Yes

9 (4.6)

No

187 (95.4)

Regular exercise
Yes

133 (67.9)

No

63 (32.1)

Menopausal status
Yes

125 (63.8)

No
Age (years)

71 (36.2)
53.76 ± 8.89

Clinical characteristics
Comorbidity
Yes

87 (44.4)

No

109 (55.6)

Use of a biological medication for RA
Yes

131 (66.8)

No

65 (33.2)

Disease duration (years)

9.72 ± 6.02

BMI (kg/m2)

24.00 ± 4.19

DAS28 score

3.77 ± 1.01

Serum CRP (mg/dL)

0.94 ± 1.07

Self-reported pain (VAS)

3.18 ± 3.03

TDQ score

12.28 ± 8.34

Correlations of demographic and clinical characteristics
with FSD

Table 3 shows the demographic and clinical characteristics
of participants with and without FSD. This univariate
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Table 2 Mean and SD of the six domains of FSFI (n = 196)
Mean

SD

Standardized
score(1)

Rank

Desire

1.98

0.97

33.0

2

Arousal

1.43

1.66

23.8

6

Lubrication

1.89

2.23

31.5

3

Domain

Orgasm

1.85

2.16

30.8

4

Satisfaction

3.25

1.21

54.2

1

Pain

1.48

1.72

24.7

5

(1)

Standardized score = mean ÷ total score*100%

analysis indicates that those with FSD were more likely to
be unemployed (p = 0.04) and older (p < 0.001), have less
education (p < 0.001), have a comorbidity (p = 0.003), and
be in menopausal status (p < 0.001). Moreover, FSD
was more common in women with a longer duration
of RA (p = 0.04), more severe depressive symptoms
(p < 0.001), higher DAS 28 score (p = 0.003), and more
pain (p = 0.03).
Independent predictors of FSD

Multiple logistic regression analysis indicated that 4
variables were significantly and independently associated
with FSD. In particular, FSD was more likely in subjects
who had a comorbidity (aOR: 2.76, 95% CI: 1.43–6.94), were
older (aOR: 1.22, 95% CI: 1.13–1.33), had a higher TDQ
score (aOR: 1.18, 95% CI: 1.08–1.26), and had a higher
DAS28 score (aOR: 1.38, 95% CI: 1.15–2.23) (Table 4).

Discussion
To the best of our knowledge, this is the first study to
investigate the prevalence and factors associated with
FSD in Chinese individuals with RA. We found that the
crude and age-standardized prevalence of FSD in our
sample were 66.8% and 48.2%, respectively. These
numbers are consistent with those of previous reports,
which indicated that the prevalence of FSD in subjects
with RA ranged from 45% to 62% [8, 13, 14]. Table 2
further demonstrates that severe FSD is primarily a
reflection of the “arousal” and “pain” domains. It may be
inferred from these findings that RA patients who have
stiffness and joint deformity in their hips or shoulders
experience difficulty with intercourse and finding a
comfortable sexual position, and this may lead to poor
sexual satisfaction [9]. In addition, the types of drugs
that patients are being prescribed, such as non-steroidal
anti-inflammatory drugs (NSAIDs), have been shown to
be related to the sexual arousal [30]. Notwithstanding
the fact that FSD is more prevalent in subjects with RA,
its detection and management are still not fully recognized as part of the routine care for this population [31].
Therefore, healthcare providers should be informed that
not only must they be aware of the occurrence of FSD

among RA patients, but they should also actively assess
the effects of medications prior to using them in treating
the related symptom of RA.
The results of our multivariate analysis indicated that
older age correlated positively with FSD, in agreement
with previous findings [8, 10, 11, 14]. In general, as
females get older, hormone production is lower, and this
may cause epithelial atrophy, decline of physical
strength, and vaginal dryness, all of which can provoke
dyspareunia and decreased libido [32]. Hormone replacement therapy might be recommended for female
RA patients who suffer from vaginal atrophy or irregular
menstrual cycles. It not only increases vaginal secretion or
the vaginal wall elasticity to enjoy the sexual life [32], but
also results in an attenuation of serum levels of interleukin
6 (IL-6) receptor, which is related to the biological activity
of IL-6 [33]. Some non-pharmacological or noninvasive
approaches, such as lubricants and vaginal estrogen
creams, may be taken into consideration [34].
Our study revealed that the presence of a chronic
medical condition significantly increased the risk of FSD
among RA patients, in agreement with previous findings
[13, 14]. This may be because the presence of a comorbid condition negatively affects a patient’s perception of
her health status, or reduces her ability to withstand
therapy-induced side effects and other complications
arising from RA. Our results also agree with those of
earlier reports which showed a greater risk of FSD
among RA patients with depressive symptoms [8, 9, 11,
13]. It is noteworthy that a review article highlighted
that some antidepressant medications, especially selective serotonin uptake inhibitors, can have deleterious
effects on sexuality because they reduce sexual arousal
and vaginal lubrication [35]. Depression is a common
psychiatric disorder among individuals with RA [36], so
clinicians should carefully appraise the effects of antidepressant medications before prescribing them to these
patients. This approach might help to reduce FSD in
this population.
Consistent with some previous studies [8, 11–13],
we also found a significantly positive correlation between DAS28 score and FSD among individuals with
RA. This implies that those with better mobility are
more likely to successfully integrate into social support networks, maintain good interpersonal relationships, require less help from others in daily activities,
and have better sexual function. This finding, however, differed from some other reports [10, 14]. This
inconsistency may be attributed to the differences in
age distribution of study subjects or the use of different statistical analyses. For example, our subjects
(average age: 53.8 years) were older than those in the
study of Costa et al. (49.7 years) [10]. It can be argued that
different physical and possibly cognitive functions may
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Table 3 Relationship of demographic and clinical characteristics with FSD in Taiwanese RA patients (n = 196)
Variable

FSD (n=131)

Non-FSD (n=65)

p

N (%) or Mean ± SD
Demographic characteristics
Educational level

<0.001

High (≥9th grade)

60 (45.8)

48 (73.8)

Low (<9th grade)

71 (54.2)

17 (26.2)

Martial status

0.33

Married

120 (91.6)

62 (95.4)

Single

11 (8.4)

3 (4.6)

Employed

52 (39.7)

36 (55.4)

Unemployed

79 (60.3)

29 (44.6)

Working status

0.04

Living status

0.12

Living alone

12 (9.2)

2 (3.1)

Cohabitating

119 (90.8)

63 (96.9)

Yes

115 (87.8)

52 (80.0)

No

16 (12.2)

13 (20.0)

Religious beliefs

0.15

Cigarette smoking

0.14

Yes

4 (3.1)

5 (7.7)

No

127 (96.9)

60 (92.3)

Yes

85 (64.9)

48 (73.8)

No

46 (35.1)

17 (26.2)

Regular exercise

0.21

Menopausal status

<0.001

Yes

96 (73.3)

30 (46.2)

No

35 (26.7)

36 (55.4)

56.19 ± 7.16

47.41 ± 8.02

Yes

68 (51.9)

19 (29.2)

No

63 (48.1)

46 (70.8)

Age (years)

<0.001

Clinical characteristics
Comorbidity

0.003

Use of a biological medication for RA

0.43

Yes

90 (68.7)

41 (63.1)

No

41 (31.3)

24 (36.9)

Disease duration (years)

10.33 ± 6.12

8.48 ± 5.45

0.04

BMI (kg/m2)

24.35 ± 4.34

23.30 ± 3.28

0.10

DAS28 score

3.92 ± 1.06

3.46 ± 0.84

0.003

Serum CRP (mg/dL)

1.05 ± 1.53

0.71 ± 2.17

0.21

Self-reported pain (VAS)

3.48 ± 3.27

2.57 ± 2.39

0.03

TDQ score

13.98 ± 8.79

8.83 ± 6.09

<0.001

have different effects on sexual function. Furthermore,
both of these former studies relied solely on univariate
analysis [10, 14], and therefore did not account for potential confounding.

The results of the present study should be interpreted
with caution because of several limitations. First, all participants were drawn from a single hospital in southern
Taiwan, so the results might not be generalizable to other
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Table 4 Multiple logistic regression analysis of the association of
demographic and clinical characteristics with FSD in Taiwanese RA
patients
Variable

Crude OR (95% CI)

Adjusted OR (95% CI)

Low (<9th grade)

3.34 (1.74-6.40)

1.55 (0.65-3.67)

High (≥9th grade)

1

1

Unemployed

1.88 (1.03-3.44)

1.32 (0.60-2.89)

Employed

1

1

Yes

3.40 (1.83-6.35)

2.67 (0.88-7.49)

No

1

1

2.61 (1.39-4.93)

2.76 (1.43-6.94)

Educational level

Working status

Menopause

Comorbidity
Yes
No
Age (years)

1

1

1.15 (1.10-1.21)

1.21 (1.13-1.32)

Disease duration (years)

1.06 (1.01-1.12)

1.03 (0.96-1.11)

DAS28 score

1.73 (1.19-2.52)

1.38 (1.15-2.23)

Self-reported pain (VAS)

1.12 (1.00-1.25)

1.01 (0.89-1.14)

TDQ score

1.11 (1.05-1.17)

1.18 (1.08-1.26)

populations. Future studies should recruit larger samples
via a nationwide survey or random sampling to improve
the representativeness of findings. Nonetheless, we calculated the sample size needed to ensure adequate statistical
power before beginning this study and obtained some statistically significant findings, so the sample size may be
considered sufficient for identifying factors associated with
FSD. However, future studies using non-RA subjects as a
reference group for comprehensive risk comparison are
still recommended. Second, this study used a crosssectional design so we cannot confirm causality. A longitudinal research design is needed to establish causal relationships, especially focusing on the long-term
relationship between FSD and clinical prognosis. Third, although we accounted for the influence of potential confounders, residual confounding might have been present
due to unmeasured confounders (such as distress mood,
coping effectiveness, diet, or genotype). Future studies are
recommended to examine these concerns via the employment of more psychometrically sound scales. Despite
these methodological concerns, this might be the first
study to assess the prevalence of FSD among individuals
with RA in Taiwan. Thus, this study can be used as a reference for the development of timely therapeutic regimens
for treatment of FSD in patients with RA.

Conclusions
Advances in medical techniques have extended the survival and improved the lives of patients with RA, but

disease symptoms and the adverse effects of different
treatments may affect the sexual health of these patients.
This study found that the crude and age-standardized
prevalence of FSD among women with RA were 66.8
and 48.2%, respectively. Those who were older, had a comorbid condition, had more depressive symptoms, and
had greater disease activity had a higher risk for FSD.
Healthcare providers should actively institute appropriate rehabilitation procedures for female RA patients with
sexual dysfunctions. Ensuring that sexual health is available to female RA patients may be an important first
step to helping them to better cope with their disease
and may also help to improve their overall quality of life
and survival.
Abbreviation
aOR: Adjusted odds ratio; BMI: Body mass index; CI: Confidence interval; CRP: Creactive protein; DAS28: Disease Activity Score in 28 Joints; DMARDs: Diseasemodifying anti-rheumatic drugs; FSFI: Female Sexual Functional Index;
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